Classical Hodgkin's lymphoma: The Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant

Haematologica

Volumn 98, Issue 8, 2013, Pages 1185-1195

  Van Den Neste, Eric ^a   Casasnovas, Olivier ^b   André, Marc ^c   Touati, Mohamed ^d   Senecal, Delphine ^e   Edeline, Véronique ^f   Stamatoullas, Aspasia ^g   Fornecker, Luc ^h   Deau, Bénédicte ⁱ   Gastinne, Thomas ^j   Reman, Oumédaly ^k   Gaillard, Isabelle ^l   Borel, Cécile ^m   Brice, Pauline ⁿ   Fermé, Christophe ^o  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^d LIMOGES UNIVERSITY HOSPITAL   (France)

^e CENTRE HOSPITALIER DE CHAMBÉRY   (France)

^f INSTITUT CURIE   (France)

^g CENTRE HENRI BECQUEREL   (France)

^h UNIVERSITY HOSPITAL OF STRASBOURG   (France)

ⁱ Institut de Cancérologie Gustave Roussy ^*  (France)

^j NANTES UNIVERSITY HOSPITAL   (France)

^k CAEN UNIVERSITY HOSPITAL   (France)

^l HENRI MONDOR HOSPITAL   (France)

^m TOULOUSE UNIVERSITY HOSPITAL   (France)

ⁿ SAINT LOUIS HOSPITAL   (France)

^o INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARBOPLATIN; CD20 ANTIGEN; CISPLATIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; NAVELBINE; OXALIPLATIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CHEMOSENSITIVITY; CLASSICAL HODGKIN LYMPHOMA; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE FREE INTERVAL; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; HUMAN; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RISK FACTOR; SALVAGE THERAPY; SCORING SYSTEM; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY; SOCIETIES, MEDICAL;

EID: 84881017942     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.072090     Document Type: Article

References (77)

1. Meyer RM, Hoppe RT. Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy. Blood. 2012;120(23):4488-95.
2. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011;117(16):4208-17.
3. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341(8852): 1051-4.
4. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002; 359(9323):2065-71.
5. Lazarus HM, Rowlings PA, Zhang MJ, Vose JM, Armitage JO, Bierman PJ, et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 1999; 17(2):534-45.
6. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood. 1997;89(3):814-22.
7. Carella AM, Congiu AM, Gaozza E, Mazza P, Ricci P, Visani G, et al. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report. J Clin Oncol. 1988;6(9): 1411-6.
8. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood. 2000;96(4):1280-6.
9. Andre M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Societe Francaise de Greffe de Moelle. J Clin Oncol. 1999;17(1): 222-9.
10. Ferme C, Mounier N, Divine M, Brice P, Stamatoullas A, Reman O, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol. 2002;20(2):467-75.
11. Morabito F, Stelitano C, Luminari S, Mammi C, Marcheselli L, Callea V, et al. The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Bone Marrow Transplant. 2006;37(3):283-8.
12. Josting P, Bierman PJ. Relapsed and refractory Hodgkin lymphoma. A Engert and SJ Horning (eds), Hodgkin Lymphoma. 2011: 203-43.
13. Brice P, Bastion Y, Divine M, Nedellec G, Ferrant A, Gabarre J, et al. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Cancer. 1996;78(6):1293-9.
14. Colpo A, Hochberg E, Chen YB. Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma. The Oncologist. 2012;17(1):80-90.
15. Smith SD, Moskowitz CH, Dean R, Pohlman B, Sobecks R, Copelan E, et al. Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres. Br J Haematol. 2011;153(3):358-63.
16. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52-9.
17. Pfreundschuh MG, Rueffer U, Lathan B, Schmitz N, Brosteanu O, Hasenclever D, et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol. 1994;12(3):580-6.
18. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol. 2002;20(1):221-30.
19. Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3): 616-23.
20. Mendler JH, Friedberg JW. Salvage therapy in Hodgkin's lymphoma. The Oncologist. 2009;14(4):425-32.
21. Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol. 2002;13(10): 1628-35.
22. Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A, Crump M. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer. 2006;106(2):353-60.
23. Baetz T, Belch A, Couban S, Imrie K, Yau J, Myers R, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 2003;14(12):1762-7.
24. Sibon D, Ertault M, Al Nawakil C, de Bazelaire C, Franchi P, Briere J, et al. Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients. Br J Haematol. 2011;153(2):191-8.
25. Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica. 2007;92(1):35-41.
26. Moore S, Kayani I, Peggs K, Qian W, Lowry L, Thomson K, et al. Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL. Br J Haematol. 2012;157(5):543-52.
27. Josting A, Muller H, Borchmann P, Baars JW, Metzner B, Dohner H, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol. 2010;28(34):5074-80.
28. Eichenauer DA, Engert A. Is there a role for BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) in relapsed Hodgkin lymphoma? Leuk Lymphoma. 2009;50(11):1733-4.
29. Gallamini A, Patti C, Viviani S, Rossi A, Fiore F, Di Raimondo F, et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol. 2011;152(5):551-60.
30. Cavalieri E, Matturro A, Annechini G, De Angelis F, Frattarelli N, Gentilini F, et al. Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma. Leuk Lymphoma. 2009;50(11):1803-8.
31. Brice P. Managing relapsed and refractory Hodgkin lymphoma. B J Haematol. 2008;141(1):3-13.
32. Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119(7): 1665-70.
33. Biswas T, Culakova E, Friedberg JW, Kelly JL, Dhakal S, Liesveld J, et al. Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma. Radiother Oncol. 2012;103(3): 367-72.
34. Tsang RW, Gospodarowicz MK, Sutcliffe SB, Crump M, Keating A. Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin's disease. PMH Lymphoma Group, and the Toronto Autologous BMT Group. Eur J Cancer. 1999;35(1):73-8.
35. Kahn S, Flowers C, Xu Z, Esiashvili N. Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma? Int J Radiat Oncol Biol Phys. 2011;81(1):175-80.
36. Josting A, Nogova L, Franklin J, Glossmann JP, Eich HT, Sieber M, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol. 2005;23(7):1522-9.
37. Brusamolino E, Bacigalupo A, Barosi G, Biti G, Gobbi PG, Levis A, et al. Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. Haematologica. 2009;94(4):550-65.
38. Corradini P, Sarina B, Farina L. Allogeneic transplantation for Hodgkin's lymphoma. Br J Haematol. 2011;152(3):261-72.
39. Peggs KS, Kayani I, Edwards N, Kottaridis P, Goldstone AH, Linch DC, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol. 2011;29(8):971-8.
40. Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(3): 455-62.
41. Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009;94(2):230-8.
42. Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study-a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97(2):310-7.
43. Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol. 2000;18(23):3918-24.
44. Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology Am Soc Hematol Educ Program. 2008:326-33.
45. Smith SM, van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO, et al. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant. 2008;14(8):904-12.
46. Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008;14(4):418-25.
47. Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116(23):4934-7.
48. Filmont JE, Gisselbrecht C, Cuenca X, Deville L, Ertault M, Brice P, et al. The impact of pre-and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer. 2007;110 (6):1361-9.
49. Cocorocchio E, Peccatori F, Vanazzi A, Piperno G, Calabrese L, Botteri E, et al. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors. Hematol Oncol. 2013;31(1):34-40.
50. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer. 2007;109(12):2481-9.
51. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, et al. Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. Biol Blood Marrow Transplant. 2013;19(3):410-7.
52. Devillier R, Coso D, Castagna L, Brenot Rossi I, Anastasia A, Chiti A, et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. Haematologica. 2012;97(7):1073-9.
53. Connors JM. Positron emission tomography in the management of Hodgkin lymphoma. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program 2011:317-22.
54. Hutchings M. How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma? Hematology Am Soc Hematol Educ Program. 2012;2012:322-7.
55. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PETScan in Lymphoma. Leuk Lymphoma. 2009;50(8):1257-60.
56. Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, Polliack A. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma. 2012;53(10);1876-81.
57. Morschhauser F, Brice P, Ferme C, Divine M, Salles G, Bouabdallah R, et al. Riskadapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol. 2008;26(36): 5980-7.
58. Brice P, Divine M, Simon D, Coiffier B, Leblond V, Simon M, et al. Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group. Ann Oncol. 1999;10(12):1485-8.
59. Fung HC, Stiff P, Schriber J, Toor A, Smith E, Rodriguez T, et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant. 2007;13(5):594-600.
60. Moskowitz CH, Yahalom J, Zelenetz AD, Zhang Z, Filippa D, Teruya-Feldstein J, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol. 2010;148(6): 890-7.
61. Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F, et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol. 1997;15(2):528-34.
62. Stiff PJ, Unger JM, Forman SJ, McCall AR, LeBlanc M, Nademanee AP, et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant. 2003;9(8):529-39.
63. Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009:507-19.
64. Jona A, Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Blood Rev. 2010;24 (6):233-8.
65. Moskowitz AJ. Novel agents in Hodgkin lymphoma. Curr Oncol Rep. 2012;14(5): 419-23.
66. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-9.
67. Rothe A, Sasse S, Goergen H, Eichenauer DA, Lohri A, Jager U, et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood. 2012;120(7):1470-2.
68. Gopal AK, Ramchandren R, O'Connor OA, Berryman RB, Advani RH, Chen R, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120(3):560-8.
69. Chen R, Palmer JM, Thomas SH, Tsai NC, Farol L, Nademanee A, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012;119 (26):6379-81.
70. Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK Centre. Haematologica. 2013;98(4):611-4.
71. Goyal SD, Bartlett NL. Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma? Curr Hematol Malig Rep. 2012;7(3):179-85.
72. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10(5):589-97.
73. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30(18):2197-203.
74. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003;98(2):310-4.
75. Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer. 2008;112(4):831-6.
76. Oki Y, Younes A. Does rituximab have a place in treating classic hodgkin lymphoma? Curr Hematol Malig Rep. 2010; 5(3):135-9.
77. Corazzelli G, Frigeri F, Marcacci G, Capobianco G, Arcamone M, Becchimanzi C, et al. Rituximab plus gemcitabine, ifosfamide, oxaliplatin (R-GIFOX) as salvage therapy for recurrent Hodgkin lymphoma. J Clin Oncol. 2009;27(15s).